Takeda Pharmaceuticals has announced a strategic partnership with Insilico Medicine aimed at enhancing early-stage drug discovery using artificial intelligence. This collaboration allows Takeda to leverage Insilico’s advanced Pharma.AI platform designed for biological target identification, molecular design, and predicting clinical trial outcomes. While the specific therapeutic areas or disease targets have not been disclosed, the deal […]
